ARDELYX, INC. (NASDAQ:ARDX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02
On March 3, 2017, the Board of Directors (the “Board”) of Ardelyx, Inc., a Delaware corporation (the “Company”), approved the following modifications to the Company’s Non-Employee Director Compensation Program (the “Director Compensation Program”): (i) the annual cash retainer for each of the Board’s non-employee directors for their service on the Board was increased from $35,000 to $40,000, and (ii) the stock option grants to non-employee directors upon their initial appointment or election to the Board was increased from 25,000 shares of the Company’s common stock (“Common Stock”) to 30,000 shares of Common Stock. These modifications to the Director Compensation Program had been recommended to the Board by the Compensation Committee of the Board.
About ARDELYX, INC. (NASDAQ:ARDX)
Ardelyx, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of minimally systemic therapeutic drugs that work in the gastrointestinal (GI) tract to treat GI and cardio-renal diseases. The Company operates through research, development and commercialization of biopharmaceutical products segment. It has discovered and designed its lead product candidate, tenapanor, which is a minimally systemic small molecule that acts locally in the GI tract to inhibit the sodium transporter sodium-hydrogen exchanger 3 (NHE3) and reduce sodium and phosphorus uptake from the gut. It is evaluating tenapanor in over two pivotal Phase III clinical studies in patients with constipation-predominant irritable bowel syndrome (IBS-C). It is developing RDX022 for the treatment of hyperkalemia. RDX022 is its oral, non-absorbed potassium-binder. Its development programs also include RDX009 Program, RDX013 Program and RDX011 Program. ARDELYX, INC. (NASDAQ:ARDX) Recent Trading Information
ARDELYX, INC. (NASDAQ:ARDX) closed its last trading session down -0.15 at 13.50 with 111,946 shares trading hands.